Transcriptional regulation of neutral sphingomyelinase 2 gene expression of a human breast cancer cell line, MCF-7, induced by the anti-cancer drug, daunorubicin

Biochimica et Biophysica Acta - Gene Regulatory Mechanisms

Volumn 1789, Issue 11-12, 2009, Pages 681-690

  Ito, Hiromi ^a   Murakami, Masashi ^a   Furuhata, Ayako ^a   Gao, Siqiang ^a   Yoshida, Kayo ^a   Sobue, Sayaka ^b   Hagiwara, Kazumi ^a   Takagi, Akira ^a   Kojima, Tetsuhito ^a   Suzuki, Motoshi ^c   Banno, Yoshiko ^d   Tanaka, Kouji ^e   Tamiya Koizumi, Keiko ^f   Kyogashima, Mamoru ^f   Nozawa, Yoshinori ^g   Murate, Takashi ^a  

^a NAGOYA UNIVERSITY   (Japan)

^b CHUBU UNIVERSITY   (Japan)

^c NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d Graduate School of Medicine   (Japan)

^e SHINSHU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^f AICHI CANCER CENTER HOSPITAL   (Japan)

^g GIFU INTERNATIONAL INSTITUTE OF BIOTECHNOLOGY   (Japan)

Author keywords

Ceramide; ChIP; Daunorubicin; EMSA; NSMase2; Promoter analysis; Sp family protein

Indexed keywords

ANTINEOPLASTIC ANTIBIOTIC; CERAMIDE; DAUNORUBICIN; NEUTRAL SPHINGOMYELINASE 1, HUMAN; NEUTRAL SPHINGOMYELINASE 3, HUMAN; NEUTRAL SPHINGOMYELINASE-1, HUMAN; SMALL INTERFERING RNA; SMPD3 PROTEIN, HUMAN; SP3 PROTEIN, HUMAN; SPHINGOMYELIN PHOSPHODIESTERASE; TRANSCRIPTION FACTOR SP1; TRANSCRIPTION FACTOR SP3;

ANIMAL; APOPTOSIS; ARTICLE; BINDING SITE; BREAST TUMOR; CELL LINE; CELL SURVIVAL; CHROMATIN IMMUNOPRECIPITATION; DRUG EFFECT; ENZYMOLOGY; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; HUMAN; METABOLISM; PATHOLOGY; PROMOTER REGION; PROTEIN BINDING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; BINDING SITES; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE; CELL LINE, TUMOR; CELL SURVIVAL; CERAMIDES; CHROMATIN IMMUNOPRECIPITATION; DAUNORUBICIN; ELECTROPHORETIC MOBILITY SHIFT ASSAY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; SP1 TRANSCRIPTION FACTOR; SP3 TRANSCRIPTION FACTOR; SPHINGOMYELIN PHOSPHODIESTERASE; TRANSFECTION;

EID: 77949321187     PISSN: 18749399     EISSN: 18764320     Source Type: Journal    
DOI: 10.1016/j.bbagrm.2009.08.006     Document Type: Article

References (45)

1. Spiegel S., Merrill A.H. Sphingolipid metabolism and cell growth regulation. FASEB J. 1996, 10:1388-1397.
2. Hannun Y.A., Obeid L.M. The ceramide-centric universe of lipid-mediated cell regulation: stress encounters of the lipid kind. J. Biol. Chem. 2002, 277:25847-25850.
3. Dbaibo G.S., Hannun Y.A. Signal transduction and the regulation of apoptosis: roles of ceramide. Apoptosis 1998, 3:317-334.
4. Mansat V., Laurent G., Levade T., Bettaieb A., Jaffrezou J.P. The protein kinase C activators phorbol esters and phosphatidylserine inhibit neutral sphingomyelinase activation, ceramide generation, and apoptosis triggered by daunorubicin. Cancer Res. 1997, 57:5300-5304.
5. Marchesini N., Hannun Y.A. Acid and neutral sphingomyelinases: roles and mechanisms of regulation. Biochem. Cell Biol. 2004, 82:27-44.
6. Sawai H., Domae N., Nagan N., Hannun Y.A. Function of the cloned putative neutral sphingomyelinase as lyso-platelet activating factor-phospholipase C. J. Biol. Chem. 1999, 274:38131-38139.
7. Marchesini N., Luberto C., Hannun Y.A. Biochemical properties of mammalian neutral sphingomyelinase 2 and its role in sphingolipid metabolism. J. Biol. Chem. 2003, 278:13775-13783.
8. Marchesini N., Osta W., Bielawski J., Luberto C., Obeid L.M., Hannun Y.A. Role for mammalian neutral sphingomyelinase 2 in confluence-induced growth arrest of MCF7 cells. J. Biol. Chem. 2004, 279:25101-25111.
9. Stoffel W., Jenke B., Block B., Zumbansen M., Koebke J. Neutral sphingomyelinase 2 (smpd3) in the control of postnatal growth and development. Proc. Natl Acad. Sci. U. S. A. 2005, 102:4554-4559.
10. Sobue S., Iwasaki T., Sugisaki C., Nagata K., Kikuchi R., Murakami M., Takagi A., Kojima T., Banno Y., Akao Y., Nozawa Y., Kannagi R., Suzuki M., Abe A., Naoe T., Murate T. Quantitative RT-PCR analysis of sphingolipid metabolic enzymes in acute leukemia and myelodysplastic syndromes. Leukemia 2006, 20:2042-2046.
11. Kim W.J., Okimoto R.A., Purton L.E., Goodwin M., Haserlat S.M., Dayyani F., Sweetser D.A., McClatchey A.I., Bernard O.A., Look A.T., Bell D.W., Scadden D.T., Haber D.A. Mutations in the neutral sphingomyelinase gene SMPD3 implicate the ceramide pathway in human leukemias. Blood 2008, 111:4716-4722.
12. Krut O., Wiegmann K., Kashkar H., Yazdanpanah B., Kronke M. Novel tumor necrosis factor-responsive mammalian neutral sphingomyelinase-3 is a C-tail-anchored protein. J. Biol. Chem. 2006, 281:13784-13793.
13. Murate T., Suzuki M., Hattori M., Takagi A., Kojima T., Tanizawa T., Asano H., Hotta T., Saito H., Yoshida S., Tamiya-Koizumi K. Up-regulation of acid sphingomyelinase during retinoic acid-induced myeloid differentiation of NB4, a human acute promyelocytic leukemia cell line. J. Biol. Chem. 2002, 277:9936-9943.
14. Liu F., Pore N., Kim M., Voong K.R., Dowling M., Maity A., Kao G.D. Regulation of histone deacetylase 4 expression by the SP family of transcription factors. Mol. Biol. Cell 2006, 17:585-597.
15. Yamada K., Tanaka T., Miyamoto K., Noguchi T. Sp family members and nuclear factor-Y cooperatively stimulate transcription from the rat pyruvate kinase M gene distal promoter region via their direct interactions. J. Biol. Chem. 2000, 275:18129-18137.
16. Satoh S., Masatoshi S., Shou Z., Yamamoto T., Ishigure T., Semii A., Yamada K., Noguchi T. Identification of cis-regulatory elements and trans-acting proteins of the rat carbohydrate response element binding protein gene. Arch. Biochem. Biophys. 2007, 461:113-122.
17. Bligh E.G., Dyer W.J. A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol. 1959, 37:911-917.
18. Sobue S., Nemoto S., Murakami M., Ito H., Kimura A., Gao S., Furuhata A., Takagi A., Kojima T., Nakamura M., Ito Y., Suzuki M., Banno Y., Nozawa Y., Murate T. Implications of sphingosine kinase 1 expression level for the cellular sphingolipid rheostat: relevance as a marker for daunorubicin sensitivity of leukemia cells. Int. J. Hematol. 2008, 87:266-275.
19. Ling M.M., Robinson B.H. Approaches to DNA mutagenesis: an overview. Anal. Biochem. 1997, 254:157-178.
20. Sobue S., Hagiwara K., Banno Y., Tamiya-Koizumi K., Suzuki M., Takagi A., Kojima T., Asano H., Nozawa Y., Murate T. Transcription factor specificity protein 1 (Sp1) is the main regulator of nerve growth factor-induced sphingosine kinase 1 gene expression of the rat pheochromocytoma cell line, PC12. J. Neurochem. 2005, 95:940-949.
21. Sobue S., Murakami M., Banno Y., Ito H., Kimura A., Gao S., Furuhata A., Takagi A., Kojima T., Suzuki M., Nozawa Y., Murate T. v-Src oncogene product increases sphingosine kinase 1 expression through mRNA stabilization: alteration of AU-rich element-binding proteins. Oncogene 2008, 27:6023-6033.
22. Li S., Zhou Y., Dong Y., Ip C. Doxorubicin and selenium cooperatively induce fas signaling in the absence of Fas/Fas ligand interaction. Anticancer Res. 2007, 27:3075-3082.
23. Wang S., Konorev E.A., Kotamraju S., Joseph J., Kalivendi S., Kalyanaraman B. Doxorubicin induces apoptosis in normal and tumor cells via distinctly different mechanisms. intermediacy of H(2)O(2)- and p53-dependent pathways. J. Biol. Chem. 2004, 279:25535-25543.
24. Grazide S., Maestre N., Veldman R.J., Bezombes C., Maddens S., Levade T., Laurent G., Jaffrezou J.P. Ara-C- and daunorubicin-induced recruitment of Lyn in sphingomyelinase-enriched membrane rafts. FASEB J. 2002, 16:1685-1687.
25. Schenck M., Carpinteiro A., Grassme H., Lang F., Gulbins E. Ceramide: physiological and pathophysiological aspects. Arch. Biochem. Biophys. 2007, 462:171-175.
26. Andrieu-Abadie N., Levade T. Sphingomyelin hydrolysis during apoptosis. Biochim. Biophys. Acta 2002, 1585:126-134.
27. Riboni L., Viani P., Bassi R., Prinetti A., Tettamanti G. The role of sphingolipids in the process of signal transduction. Prog. Lipid Res. 1997, 36:153-195.
28. Clarke C.J., Snook C.F., Tani M., Matmati N., Marchesini N., Hannun Y.A. The extended family of neutral sphingomyelinases. Biochemistry 2006, 45:11247-11256.
29. Yabu T., Imamura S., Yamashita M., Okazaki T. Identification of Mg2+-dependent neutral sphingomyelinase 1 as a mediator of heat stress-induced ceramide generation and apoptosis. J. Biol. Chem. 2008.
30. Hayashi Y., Kiyono T., Fujita M., Ishibashi M. cca1 is required for formation of growth-arrested confluent monolayer of rat 3Y1 cells. J. Biol. Chem. 1997, 272:18082-18086.
31. Nemoto S., Nakamura M., Osawa Y., Kono S., Itoh Y., Okano Y., Murate T., Hara A., Ueda H., Nozawa Y., Banno Y. Sphingosine kinase isoforms regulate oxaliplatin sensitivity of human colon cancer cells through ceramide accumulation and AKT activtion. J. Biol. Chem. 2009, 284:10422-10432.
32. Corcoran C.A., He Q., Ponnusamy S., Ogretmen B., Huang Y., Sheikh M.S. Neutral sphingomyelinase-3 is a DNA damage and nongenotoxic stress-regulated gene that is deregulated in human malignancies. Mol. Cancer Res. 2008, 6:795-807.
33. Laurent G., Jaffrezou J.P. Signaling pathways activated by daunorubicin. Blood 2001, 98:913-924.
34. Ogretmen B., Kraveka J.M., Schady D., Usta J., Hannun Y.A., Obeid L.M. Molecular mechanisms of ceramide-mediated telomerase inhibition in the A549 human lung adenocarcinoma cell line. J. Biol. Chem. 2001, 276:32506-32514.
35. Jaffrezou J.P., Levade T., Bettaieb A., Andrieu N., Bezombes C., Maestre N., Vermeersch S., Rousse A., Laurent G. Daunorubicin-induced apoptosis: triggering of ceramide generation through sphingomyelin hydrolysis. EMBO J. 1996, 15:2417-2424.
36. Langmann T., Buechler C., Ries S., Schaeffler A., Aslanidis C., Schuierer M., Weiler M., Sandhoff K., de Jong P.J., Schmitz G. Transcription factors Sp1 and AP-2 mediate induction of acid sphingomyelinase during monocytic differentiation. J. Lipid Res. 1999, 40:870-880.
37. Mansilla S., Portugal J. Sp1 transcription factor as a target for anthracyclines: effects on gene transcription. Biochimie 2008, 90:976-987.
38. Liu Y.Y., Yu J.Y., Yin D., Patwardhan G.A., Gupta V., Hirabayashi Y., Holleran W.M., Giuliano A.E., Jazwinski S.M., Gouaze-Andersson V., Consoli D.P., Cabot M.C. A role for ceramide in driving cancer cell resistance to doxorubicin. FASEB J. 2008, 22:2541-2551.
39. Uchida Y., Itoh M., Taguchi Y., Yamaoka S., Umehara H., Ichikawa S., Hirabayashi Y., Holleran W.M., Okazaki T. Ceramide reduction and transcriptional up-regulation of glucosylceramide synthase through doxorubicin-activated Sp1 in drug-resistant HL-60/ADR cells. Cancer Res. 2004, 64:6271-6279.
40. Hagen G., Muller S., Beato M., Suske G. Sp1-mediated transcriptional activation is repressed by Sp3. EMBO J. 1994, 13:3843-3851.
41. Majello B., De Luca P., Hagen G., Suske G., Lania L. Different members of the Sp1 multigene family exert opposite transcriptional regulation of the long terminal repeat of HIV-1. Nucleic Acids Res. 1994, 22:4914-4921.
42. Yu B., Datta P.K., Bagchi S. Stability of the Sp3-DNA complex is promoter-specific: Sp3 efficiently competes with Sp1 for binding to promoters containing multiple Sp-sites. Nucleic Acids Res. 2003, 31:5368-5376.
43. Bouwman P., Philipsen S. Regulation of the activity of Sp1-related transcription factors. Mol. Cell. Endocrinol. 2002, 195:27-38.
44. Suske G. The Sp-family of transcription factors. Gene 1999, 238:291-300.
45. Xu J., Zhou J.Y., Wei W.Z., Philipsen S., Wu G.S. Sp1-mediated TRAIL induction in chemosensitization. Cancer Res. 2008, 68:6718-6726.